Medicare adds fourth drug compendium for Part B coverage
Executive Summary
Elsevier Gold Standard's Clinical Pharmacology is officially recognized as a valid reference for determining off-label coverage of cancer drugs under Medicare Part B. The decision completes CMS' review of compendia recognition requests received earlier this year. Of four compendia nominated, three have been officially recognized by the agency; the other two are Thomson Micromedex's DrugDex and the National Comprehensive Cancer Network Drugs & Biologics Compendium. They join the currently recognized compendium that is still in print - American Hospital Formulary Service-Drug Information - bringing to four the number of officially recognized compendia that now may be used for coverage decisions